Salix Drug Patent Portfolio
Salix owns 12 orange book drugs protected by 112 US patents with Metozolv Odt having the least patent protection, holding only 1 patent. And Xifaxan with maximum patent protection, holding 35 patents. Given below is the list of Salix's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10011637 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | 05 Jun, 2034 | Active |
| US11142549 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | 05 Jun, 2034 | Active |
| US11834521 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | 05 Jun, 2034 | Active |
| US12146003 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | 05 Jun, 2034 | Active |
| US10016504 | Compositions | 10 Sep, 2033 | Active |
| US10918723 | Colon cleansing compositions and methods of use | 10 Sep, 2033 | Active |
| US12083179 | Colon cleansing compositions and method of use | 10 Sep, 2033 | Active |
| US8999313 | Compositions | 10 Sep, 2033 | Active |
| US9326969 | Compositions | 10 Sep, 2033 | Active |
| US9707297 | Compositions | 10 Sep, 2033 | Active |
| US9616097 | Formulations of guanylate cyclase C agonists and methods of use | 20 Aug, 2032 | Active |
| US9592252 | Colonoscopy—preparation | 11 Aug, 2032 | Active |
| US10646512 | Colonoscopy - preparation | 25 Mar, 2032 | Active |
| US10780112 | Colonoscopy-preparation | 09 Mar, 2032 | Active |
| US10792306 | Colonoscopy—preparation | 09 Mar, 2032 | Active |
| US11529368 | Colonoscopy—preparation | 09 Mar, 2032 | Active |
| US11319346 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | 01 Mar, 2032 | Active |
| US9610321 | Formulations of guanylate cyclase C agonists and methods of use | 15 Sep, 2031 | Active |
| US9919024 | Formulations of guanylate cyclase C agonists and methods of use | 15 Sep, 2031 | Active |
| US9925231 | Formulations of guanylate cyclase C agonists and methods of use | 15 Sep, 2031 | Active |
| US10307375 | Controlled release and taste masking oral pharmaceutical composition | 07 Sep, 2031 | Active |
| US10660858 | Controlled release and taste masking oral pharmaceutical composition | 07 Sep, 2031 | Active |
| US8895064 | Controlled release and taste masking oral pharmaceutical composition | 07 Sep, 2031 | Active |
| US9132093 | Controlled release and taste making oral pharmaceutical composition | 07 Sep, 2031 | Active |
| US9192581 | Controlled release and taste masking oral pharmaceutical composition | 07 Sep, 2031 | Active |
| US10307417 | Oral formulations and lipophilic salts of methylnaltrexone | 10 Mar, 2031 | Active |
| US10376505 | Oral formulations and lipophilic salts of methylnaltrexone | 10 Mar, 2031 | Active |
| US8524276 | Oral formulations and lipophilic salts of methylnaltrexone | 10 Mar, 2031 | Active |
| US8956651 | Oral formulations and lipophilic salts of methylnal trexone | 10 Mar, 2031 | Active |
| US9314461 | Oral formulations and lipophilic salts of methylnaltrexone | 10 Mar, 2031 | Active |
| US8247425 | Peripheral opioid receptor antagonists and uses thereof | 31 Dec, 2030 | Active |
| US8865688 | Compositions and methods for treatment of bowel diseases with granulated mesalamine | 01 May, 2030 | Active |
| US10314828 | Methods of treating hepatic encephalopathy | 02 Oct, 2029 | Active |
| US8642573 | Methods of treating hepatic encephalopathy | 02 Oct, 2029 | Active |
| US8969398 | Methods of treating hepatic encephalopathy | 02 Oct, 2029 | Active |
| US8420663 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US8822490 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US9180125 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US9492445 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US9724343 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US10335397 | Methods of treating hepatic encephalopathy | 24 Jul, 2029 | Active |
| US10709694 | Methods of treating hepatic encephalopathy | 24 Jul, 2029 | Active |
| US7928115 | Methods of treating travelers diarrhea and hepatic encephalopathy | 24 Jul, 2029 | Active |
| US8829017 | Methods of treating traveler's diarrhea and hepatic encephalopathy | 24 Jul, 2029 | Active |
| US8946252 | Methods of treating traveler's diarrhea and hepatic encephalopathy | 24 Jul, 2029 | Active |
| US9421195 | Methods of treating hepatic encephalopathy | 24 Jul, 2029 | Active |
| US9629828 | Methods of treating traveler's diarrhea and hepatic encephalopathy | 24 Jul, 2029 | Active |
| US8309569 | Methods for treating diarrhea-associated irritable bowel syndrome | 18 Jul, 2029 | Active |
| US10456384 | Methods for treating irritable bowel syndrome (IBS) | 26 Feb, 2029 | Active |
| US10765667 | Methods for treating irritable bowel syndrome (IBS) | 26 Feb, 2029 | Active |
| US11564912 | Methods for treating irritable bowel syndrome (IBS) | 26 Feb, 2029 | Active |
| US11779571 | Methods for treating irritable bowel syndrome (IBS) | 26 Feb, 2029 | Active |
| US7687075 | Colonic purgative composition with soluble binding agent | 22 Jun, 2028 | Active |
| US7041786 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis | 30 Jan, 2028 | Active |
| US8193196 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 02 Sep, 2027 | Active |
| US12303592 | Formulations for parenteral delivery of compounds and uses thereof | 03 Aug, 2027 | Active |
| US10703763 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 27 Feb, 2026 | Active |
| US8518949 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 27 Feb, 2026 | Active |
| US8741904 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 27 Feb, 2026 | Active |
| US9271968 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 27 Feb, 2026 | Active |
| US7906542 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin | 01 Jun, 2025 | Expired |
| US7915275 | Use of polymorphic forms of rifaximin for medical preparations | 23 Feb, 2025 | Expired |
| US7658944 | Solid dosage form comprising a fibrate | 09 Dec, 2024 | Expired |
| US8124125 | Solid dosage form comprising a fibrate | 01 Oct, 2024 | Expired |
| US8481078 | Solid dosage form comprising a fibrate | 01 Oct, 2024 | Expired |
| US9173847 | Tablet comprising a fibrate | 01 Oct, 2024 | Expired |
| US7169381 | Colon cleansing compositions and methods | 01 Sep, 2024 | Expired |
| US7658914 | Colon cleansing compositions | 01 Sep, 2024 | Expired |
| US7045620 | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations | 19 Jun, 2024 | Expired |
| US7612199 | Polymorphic forms α, β, and γ of rifaximin | 19 Jun, 2024 | Expired |
| US7902206 | Polymorphic forms α, β and γ of rifaximin | 19 Jun, 2024 | Expired |
| US8158644 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin | 19 Jun, 2024 | Expired |
| US8158781 | Polymorphic forms α, β and γ of rifaximin | 19 Jun, 2024 | Expired |
| US8835452 | Polymorphic forms α, β and γ of rifaximin | 19 Jun, 2024 | Expired |
| US8853231 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin | 19 Jun, 2024 | Expired |
| US10376584 | Stable pharmaceutical formulations of methylnaltrexone | 08 Apr, 2024 | Expired |
| US8552025 | Stable methylnaltrexone preparation | 08 Apr, 2024 | Expired |
| US9669096 | Stable pharmaceutical formulations of methylnaltrexone | 08 Apr, 2024 | Expired |
| US7799897 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis | 09 Jun, 2022 | Expired |
| US8637451 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis | 28 Mar, 2022 | Expired |
| US10064878 | Controlled release and taste masking oral pharmaceutical compositions | 09 Jun, 2020 | Expired |
| US10105374 | Controlled release and taste masking oral pharmaceutical compositions | 09 Jun, 2020 | Expired |
| US10143698 | Controlled release and taste masking oral pharmaceutical compositions | 09 Jun, 2020 | Expired |
| US7410651 | Controlled release and taste masking oral pharmaceutical composition | 09 Jun, 2020 | Expired |
| US7431943 | Controlled release and taste masking oral pharmaceutical compositions | 09 Jun, 2020 | Expired |
| US8293273 | Controlled release and taste masking oral pharmaceutical composition | 09 Jun, 2020 | Expired |
| US8784888 | Controlled release and taste masking oral pharmaceutical composition | 09 Jun, 2020 | Expired |
| US9320716 | Controlled release and taste masking oral pharmaceutical compositions | 09 Jun, 2020 | Expired |
| US9532954 | Controlled release and taste masking oral pharmaceutical compositions | 09 Jun, 2020 | Expired |
| USRE43799 | Controlled release and taste masking oral pharmaceutical composition | 09 Jun, 2020 | Expired |
| US6861053 | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth | 11 Aug, 2019 | Expired |
| US7452857 | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth | 11 Aug, 2019 | Expired |
| US7605240 | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth | 11 Aug, 2019 | Expired |
| US7718608 | Methods of treating a subject suffering from irritable bowel syndrome | 11 Aug, 2019 | Expired |
| US7935799 | Methods of treating diarrhea caused by small intestinal bacterial overgrowth | 11 Aug, 2019 | Expired |
| US6551620 | Pellet formulation for the treatment of the intestinal tract | 20 Apr, 2018 | Expired |
| US8337886 | Pellet formulation for the treatment of the intestinal tract | 20 Apr, 2018 | Expired |
| US8496965 | Pellet formulation for the treatment of the intenstinal tract | 20 Apr, 2018 | Expired |
| US8911778 | Pellet formulation for the treatment of the intestinal tract | 20 Apr, 2018 | Expired |
| US8940328 | Pellet formulation for the treatment of the intestinal tract | 20 Apr, 2018 | Expired |
| US8956647 | Pellet formulation for the treatment of the intestinal tract | 20 Apr, 2018 | Expired |
| US6559158 | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects | 03 Nov, 2017 | Expired |
| US6413549 | Fast-Dispersing solid oral dosage form containing coarse particles | 11 Jul, 2017 | Expired |
| US5840737 | Omeprazole solution and method for using same | 16 Jul, 2016 | Expired |
| US6489346 | Substituted benzimidazole dosage forms and method of using same | 16 Jul, 2016 | Expired |
| US6645988 | Substituted benzimidazole dosage forms and method of using same | 16 Jul, 2016 | Expired |
| US6699885 | Substituted benzimidazole dosage forms and methods of using same | 16 Jul, 2016 | Expired |
| US6780882 | Substituted benzimidazole dosage forms and method of using same | 16 Jul, 2016 | Expired |
| US7399772 | Substituted benzimidazole dosage forms and method of using same | 16 Jul, 2016 | Expired |
| USRE45198 | Omeprazole solution and method for using same | 15 Jul, 2016 | Expired |
| US5914122 | Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams | 19 Dec, 2015 | Expired |
| US5616346 | Non-aqueous colonic purgative formulations | 18 May, 2013 | Expired |
Latest Legal Activities on Salix's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Salix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US8293273 (Litigated) |
|
Expire Patent
Critical
| 03 Jun, 2024 | US9320716 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Apr, 2024 | US8309569 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Mar, 2024 | US10792306 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2024 | US10780112 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Feb, 2024 | US10765667 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8247425 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jan, 2024 | US9421195 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Dec, 2023 | US10703763 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Dec, 2023 | US10709694 |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Dec, 2023 | US9320716 |
| Sequence Moved to Public Database | 08 Dec, 2023 | US11834521 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Dec, 2023 | US11834521 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Dec, 2023 | US11834521 |
|
Email Notification
Critical
| 05 Dec, 2023 | US11834521 |
Salix's Drug Patent Litigations
Salix's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 11, 2016, against patent number US8865688. The petitioner MycoNovo, Inc. et al., challenged the validity of this patent, with Salix Pharmaceuticals, Ltd. et al. as the respondent. Click below to track the latest information on how companies are challenging Salix's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7041786 | March, 2022 |
Final Written Decision - Appealed
(08 Sep, 2023)
| Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US7041786 | October, 2022 |
Final Written Decision
(08 Sep, 2023)
| Bausch Health Ireland Limited et al. | MSN Laboratories Private Ltd. et al. |
| US7041786 | October, 2022 |
Final Written Decision - Appealed
(08 Sep, 2023)
| Bausch Health Ireland Limited et al. | MSN Laboratories Private Ltd. et al. |
| US7041786 | March, 2022 |
Final Written Decision
(08 Sep, 2023)
| Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9919024 | June, 2022 |
Institution Denied
(04 Jan, 2023)
| Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9925231 | June, 2022 |
Institution Denied
(04 Jan, 2023)
| Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9610321 | June, 2022 |
Institution Denied
(04 Jan, 2023)
| Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9616097 | June, 2022 |
Institution Denied
(04 Jan, 2023)
| Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9320716 | October, 2017 |
Terminated-Settled
(23 Apr, 2018)
| Cosmo Technologies Limited | Argentum Pharmaceuticals LLC |
| US9320716 | March, 2017 |
Terminated-Settled
(17 Jan, 2018)
| ||
| US8784888 | March, 2017 |
Terminated-Settled
(20 Sep, 2017)
| ||
| US8865688 | December, 2015 |
FWD Entered
(19 May, 2017)
| SALIX PHARMACEUTICALS, LTD. | GeneriCo, LLC |
| US8865688 | December, 2015 |
Final Written Decision
(19 May, 2017)
| SALIX PHARMACEUTICALS, LTD. et al. | GeneriCo, LLC et al. |
| US8865688 | July, 2016 |
Terminated
(30 Nov, 2016)
| Salix Pharmaceuticals, Ltd. et al. | Mylan Pharmaceuticals Inc. et al. |
| US8865688 | July, 2016 |
Terminated
(30 Nov, 2016)
| Salix Pharmaceuticals, Ltd. et al. | MycoNovo, Inc. et al. |
Salix Drug Patents' Oppositions Filed in EPO
Salix drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 08, 2008, by Interquim, S.A. De C.V.. This opposition was filed on patent number EP04005541A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP09818544A | Sep, 2020 | Hollatz, Christian | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | Aera A/S | Granted and Under Opposition |
| EP09818544A | Aug, 2020 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP09818544A | Aug, 2020 | CMS Cameron McKenna Nabarro Olswang LLP | Granted and Under Opposition |
| EP09715020A | Dec, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP09715020A | Dec, 2019 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP09715020A | Dec, 2019 | Sandoz GmbH | Granted and Under Opposition |
| EP10184575A | Sep, 2015 | Actavis Group PTC ehf | Revoked |
| EP10184575A | Sep, 2015 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP10184684A | Sep, 2015 | Actavis Group PTC ehf | Revoked |
| EP04759349A | Sep, 2015 | Actavis Group PTC ehf | Patent maintained as amended |
| EP04759349A | Sep, 2015 | Fresenius Kabi Deutschland GmbH | Patent maintained as amended |
| EP10184684A | Sep, 2015 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP05004695A | Jun, 2015 | Sandoz GmbH | Revoked |
| EP02721604A | Apr, 2010 | Hill, Christopher Michael | Patent maintained as amended |
| EP02721604A | Apr, 2010 | CombiMab, Inc. | Patent maintained as amended |
| EP03758361A | May, 2009 | Teva Pharmaceutical Industries LTD. | Opposition procedure closed |
| EP04005541A | Feb, 2008 | Interquim, S.A. De C.V. | Opposition rejected |
Salix's Family Patents
Salix drugs have patent protection in a total of 54 countries. It's US patent count contributes only to 28.7% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Salix Drug List
Given below is the complete list of Salix's drugs and the patents protecting them.
1. Apriso
Apriso is protected by 7 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8865688 | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
01 May, 2030
(4 years from now)
| Active |
| US6551620 | Pellet formulation for the treatment of the intestinal tract |
20 Apr, 2018
(7 years ago)
| Expired |
| US8337886 | Pellet formulation for the treatment of the intestinal tract |
20 Apr, 2018
(7 years ago)
| Expired |
| US8496965 | Pellet formulation for the treatment of the intenstinal tract |
20 Apr, 2018
(7 years ago)
| Expired |
| US8911778 | Pellet formulation for the treatment of the intestinal tract |
20 Apr, 2018
(7 years ago)
| Expired |
| US8940328 | Pellet formulation for the treatment of the intestinal tract |
20 Apr, 2018
(7 years ago)
| Expired |
| US8956647 | Pellet formulation for the treatment of the intestinal tract |
20 Apr, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apriso's drug page
2. Fenoglide
Fenoglide is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7658944 | Solid dosage form comprising a fibrate |
09 Dec, 2024
(1 year, 30 days ago)
| Expired |
| US8124125 | Solid dosage form comprising a fibrate |
01 Oct, 2024
(1 year, 3 months ago)
| Expired |
| US8481078 | Solid dosage form comprising a fibrate |
01 Oct, 2024
(1 year, 3 months ago)
| Expired |
| US9173847 | Tablet comprising a fibrate |
01 Oct, 2024
(1 year, 3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fenoglide's drug page
3. Metozolv Odt
Metozolv Odt is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6413549 | Fast-Dispersing solid oral dosage form containing coarse particles |
11 Jul, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metozolv Odt's drug page
4. Moviprep
Moviprep is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7169381 | Colon cleansing compositions and methods |
01 Sep, 2024
(1 year, 4 months ago)
| Expired |
| US7658914 | Colon cleansing compositions |
01 Sep, 2024
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Moviprep's drug page
5. Osmoprep
Osmoprep is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7687075 | Colonic purgative composition with soluble binding agent |
22 Jun, 2028
(2 years from now)
| Active |
| US5616346 | Non-aqueous colonic purgative formulations |
18 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Osmoprep's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Plenvu
Plenvu is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10016504 | Compositions |
10 Sep, 2033
(7 years from now)
| Active |
| US10918723 | Colon cleansing compositions and methods of use |
10 Sep, 2033
(7 years from now)
| Active |
| US12083179 | Colon cleansing compositions and method of use |
10 Sep, 2033
(7 years from now)
| Active |
| US8999313 | Compositions |
10 Sep, 2033
(7 years from now)
| Active |
| US9326969 | Compositions |
10 Sep, 2033
(7 years from now)
| Active |
| US9707297 | Compositions |
10 Sep, 2033
(7 years from now)
| Active |
| US9592252 | Colonoscopy—preparation |
11 Aug, 2032
(6 years from now)
| Active |
| US10646512 | Colonoscopy - preparation |
25 Mar, 2032
(6 years from now)
| Active |
| US10780112 | Colonoscopy-preparation |
09 Mar, 2032
(6 years from now)
| Active |
| US10792306 | Colonoscopy—preparation |
09 Mar, 2032
(6 years from now)
| Active |
| US11529368 | Colonoscopy—preparation |
09 Mar, 2032
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Plenvu's drug page
7. Relistor
Relistor is protected by 16 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10307417 | Oral formulations and lipophilic salts of methylnaltrexone |
10 Mar, 2031
(5 years from now)
| Active |
| US10376505 | Oral formulations and lipophilic salts of methylnaltrexone |
10 Mar, 2031
(5 years from now)
| Active |
| US8524276 | Oral formulations and lipophilic salts of methylnaltrexone |
10 Mar, 2031
(5 years from now)
| Active |
| US8956651 | Oral formulations and lipophilic salts of methylnal trexone |
10 Mar, 2031
(5 years from now)
| Active |
| US9314461 | Oral formulations and lipophilic salts of methylnaltrexone |
10 Mar, 2031
(5 years from now)
| Active |
| US8247425 | Peripheral opioid receptor antagonists and uses thereof |
31 Dec, 2030
(4 years from now)
| Active |
| US8420663 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(3 years from now)
| Active |
| US8822490 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(3 years from now)
| Active |
| US9180125 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(3 years from now)
| Active |
| US9492445 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(3 years from now)
| Active |
| US9724343 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(3 years from now)
| Active |
| US12303592 | Formulations for parenteral delivery of compounds and uses thereof |
03 Aug, 2027
(1 year, 6 months from now)
| Active |
| US10376584 | Stable pharmaceutical formulations of methylnaltrexone |
08 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US8552025 | Stable methylnaltrexone preparation |
08 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US9669096 | Stable pharmaceutical formulations of methylnaltrexone |
08 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US6559158 | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
03 Nov, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Relistor's drug page
8. Trulance
Trulance is protected by 12 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10011637 | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
05 Jun, 2034
(8 years from now)
| Active |
| US11142549 | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
05 Jun, 2034
(8 years from now)
| Active |
| US11834521 | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
05 Jun, 2034
(8 years from now)
| Active |
| US12146003 | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
05 Jun, 2034
(8 years from now)
| Active |
| US9616097 | Formulations of guanylate cyclase C agonists and methods of use |
20 Aug, 2032
(6 years from now)
| Active |
| US11319346 | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
01 Mar, 2032
(6 years from now)
| Active |
| US9610321 | Formulations of guanylate cyclase C agonists and methods of use |
15 Sep, 2031
(5 years from now)
| Active |
| US9919024 | Formulations of guanylate cyclase C agonists and methods of use |
15 Sep, 2031
(5 years from now)
| Active |
| US9925231 | Formulations of guanylate cyclase C agonists and methods of use |
15 Sep, 2031
(5 years from now)
| Active |
| US7041786 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
30 Jan, 2028
(2 years from now)
| Active |
| US7799897 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
09 Jun, 2022
(3 years ago)
| Expired |
| US8637451 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
28 Mar, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trulance's drug page
9. Uceris
Uceris is protected by 16 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10307375 | Controlled release and taste masking oral pharmaceutical composition |
07 Sep, 2031
(5 years from now)
| Active |
| US10660858 | Controlled release and taste masking oral pharmaceutical composition |
07 Sep, 2031
(5 years from now)
| Active |
| US8895064 | Controlled release and taste masking oral pharmaceutical composition |
07 Sep, 2031
(5 years from now)
| Active |
| US9132093 | Controlled release and taste making oral pharmaceutical composition |
07 Sep, 2031
(5 years from now)
| Active |
| US9192581 | Controlled release and taste masking oral pharmaceutical composition |
07 Sep, 2031
(5 years from now)
| Active |
| US10064878 | Controlled release and taste masking oral pharmaceutical compositions |
09 Jun, 2020
(5 years ago)
| Expired |
| US10105374 | Controlled release and taste masking oral pharmaceutical compositions |
09 Jun, 2020
(5 years ago)
| Expired |
| US10143698 | Controlled release and taste masking oral pharmaceutical compositions |
09 Jun, 2020
(5 years ago)
| Expired |
| US7410651 | Controlled release and taste masking oral pharmaceutical composition |
09 Jun, 2020
(5 years ago)
| Expired |
| US7431943 | Controlled release and taste masking oral pharmaceutical compositions |
09 Jun, 2020
(5 years ago)
| Expired |
| US8293273 | Controlled release and taste masking oral pharmaceutical composition |
09 Jun, 2020
(5 years ago)
| Expired |
| US8784888 | Controlled release and taste masking oral pharmaceutical composition |
09 Jun, 2020
(5 years ago)
| Expired |
| US9320716 | Controlled release and taste masking oral pharmaceutical compositions |
09 Jun, 2020
(5 years ago)
| Expired |
| US9532954 | Controlled release and taste masking oral pharmaceutical compositions |
09 Jun, 2020
(5 years ago)
| Expired |
| USRE43799 | Controlled release and taste masking oral pharmaceutical composition |
09 Jun, 2020
(5 years ago)
| Expired |
| US5914122 | Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams |
19 Dec, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Uceris's drug page
10. Visicol
Visicol is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5616346 | Non-aqueous colonic purgative formulations |
18 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Visicol's drug page
11. Xifaxan
Xifaxan is protected by 35 patents, out of which 14 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10314828 | Methods of treating hepatic encephalopathy |
02 Oct, 2029
(3 years from now)
| Active |
| US8642573 | Methods of treating hepatic encephalopathy |
02 Oct, 2029
(3 years from now)
| Active |
| US8969398 | Methods of treating hepatic encephalopathy |
02 Oct, 2029
(3 years from now)
| Active |
| US10314828 | Methods of treating hepatic encephalopathy |
24 Jul, 2029
(3 years from now)
| Active |
| US10335397 | Methods of treating hepatic encephalopathy |
24 Jul, 2029
(3 years from now)
| Active |
| US10709694 | Methods of treating hepatic encephalopathy |
24 Jul, 2029
(3 years from now)
| Active |
| US7928115 | Methods of treating travelers diarrhea and hepatic encephalopathy |
24 Jul, 2029
(3 years from now)
| Active |
| US8829017 | Methods of treating traveler's diarrhea and hepatic encephalopathy |
24 Jul, 2029
(3 years from now)
| Active |
| US8946252 | Methods of treating traveler's diarrhea and hepatic encephalopathy |
24 Jul, 2029
(3 years from now)
| Active |
| US9421195 | Methods of treating hepatic encephalopathy |
24 Jul, 2029
(3 years from now)
| Active |
| US9629828 | Methods of treating traveler's diarrhea and hepatic encephalopathy |
24 Jul, 2029
(3 years from now)
| Active |
| US8309569 | Methods for treating diarrhea-associated irritable bowel syndrome |
18 Jul, 2029
(3 years from now)
| Active |
| US10456384 | Methods for treating irritable bowel syndrome (IBS) |
26 Feb, 2029
(3 years from now)
| Active |
| US10765667 | Methods for treating irritable bowel syndrome (IBS) |
26 Feb, 2029
(3 years from now)
| Active |
| US11564912 | Methods for treating irritable bowel syndrome (IBS) |
26 Feb, 2029
(3 years from now)
| Active |
| US11779571 | Methods for treating irritable bowel syndrome (IBS) |
26 Feb, 2029
(3 years from now)
| Active |
| US8193196 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
02 Sep, 2027
(1 year, 7 months from now)
| Active |
| US10703763 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
27 Feb, 2026
(a month from now)
| Active |
| US8518949 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
27 Feb, 2026
(a month from now)
| Active |
| US8741904 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
27 Feb, 2026
(a month from now)
| Active |
| US9271968 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
27 Feb, 2026
(a month from now)
| Active |
| US7906542 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
01 Jun, 2025
(7 months ago)
| Expired |
| US7915275 | Use of polymorphic forms of rifaximin for medical preparations |
23 Feb, 2025
(10 months ago)
| Expired |
| US7045620 | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
19 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US7612199 | Polymorphic forms α, β, and γ of rifaximin |
19 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US7902206 | Polymorphic forms α, β and γ of rifaximin |
19 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US8158644 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
19 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US8158781 | Polymorphic forms α, β and γ of rifaximin |
19 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US8835452 | Polymorphic forms α, β and γ of rifaximin |
19 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US8853231 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
19 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US6861053 | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
11 Aug, 2019
(6 years ago)
| Expired |
| US7452857 | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
11 Aug, 2019
(6 years ago)
| Expired |
| US7605240 | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
11 Aug, 2019
(6 years ago)
| Expired |
| US7718608 | Methods of treating a subject suffering from irritable bowel syndrome |
11 Aug, 2019
(6 years ago)
| Expired |
| US7935799 | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
11 Aug, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xifaxan's drug page
12. Zegerid
Zegerid is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5840737 | Omeprazole solution and method for using same |
16 Jul, 2016
(9 years ago)
| Expired |
| US6489346 | Substituted benzimidazole dosage forms and method of using same |
16 Jul, 2016
(9 years ago)
| Expired |
| US6645988 | Substituted benzimidazole dosage forms and method of using same |
16 Jul, 2016
(9 years ago)
| Expired |
| US6699885 | Substituted benzimidazole dosage forms and methods of using same |
16 Jul, 2016
(9 years ago)
| Expired |
| US6780882 | Substituted benzimidazole dosage forms and method of using same |
16 Jul, 2016
(9 years ago)
| Expired |
| US7399772 | Substituted benzimidazole dosage forms and method of using same |
16 Jul, 2016
(9 years ago)
| Expired |
| USRE45198 | Omeprazole solution and method for using same |
15 Jul, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zegerid's drug page